MENLO PARK, Calif.--(BUSINESS WIRE)--Refuge Biotechnologies, Inc. ("Refuge"), a synthetic biology company developing intelligent cell therapeutics for cancer immunotherapy, today announced that Bing Wang, Ph.D., Co-Founder and Chief Executive Officer, will present a corporate update on Tuesday, January 14, 2020 at Biotech Showcase™ being held in San Francisco, from January 13-15, 2020.
The corporate presentation will focus on design of intelligent therapeutic cells by leveraging gene engineering technology called CRISPR activation (CRISPRa) and CRISPR interference (CRISPRi). Recent data supporting the company’s lead pipeline candidate, a HER2 CAR-T plus PD-1 knockdown system for various solid tumors, including head and neck, breast and gastrointestinal cancers will be shared.
Details of the presentation are as follows:
Date and Time: Tuesday, January 14, 2020 at 11:15 a.m. PT
Location: Hilton San Francisco Times Square
Track: Franciscan C (Ballroom Level)
About Refuge Biotechnologies
Refuge Biotechnologies is a synthetic biology company developing intelligent cell therapeutics for cancer immunotherapy. Refuge's proprietary receptor-dCas platform leverages a unique gene engineering approach based on precision CRISPR activation (CRISPRa) and CRISPR interference (CRISPRi). By connecting ligand specific receptors to dCas, Refuge enables cells to sense its surroundings and conditionally activate or repress multiple genes when they encounter specific external antigens. In particular, with receptor-dCas, immune cells can now be engineered to conditionally turn off certain genes, such as PD-1, to generate more potent CAR-T immune cells when it senses the presence of a tumor cell. For further information, please visit www.refugebiotech.com.